STOCK TITAN

Arcellx Inc - ACLX STOCK NEWS

Welcome to our dedicated news page for Arcellx (Ticker: ACLX), a resource for investors and traders seeking the latest updates and insights on Arcellx.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Arcellx's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Arcellx's position in the market.

Rhea-AI Summary
Arcellx, Inc. (NASDAQ: ACLX) announces FDA lifting partial clinical hold on CART-ddBCMA drug, expects to present preliminary data from iMMagine-1 study in 2H'24. Cash, cash equivalents, and marketable securities of $506.5 million will fund operations into 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.18%
Tags
-
Rhea-AI Summary
Arcellx, Inc. reports financial results for Q1 2023, with cash, cash equivalents, and marketable securities of $533.6 million. Collaboration revenue was $17.9 million. R&D expenses increased by $14.8 million. G&A expenses increased by $7.4 million. Net loss for Q1 2023 was $27.3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.68%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.84%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.8%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
conferences
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.01%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.24%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.24%
Tags
none
Arcellx Inc

Nasdaq:ACLX

ACLX Rankings

ACLX Stock Data

2.94B
34.18M
12.8%
90.19%
7.14%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Gaithersburg

About ACLX

Arcellx Inc. is a clinical-stage biotechnology company. The Company is focused developing controllable cell therapies for the treatment of patients with cancer and other incurable diseases.